Preclinical studies with synthetic peptides in systemic lupus erythematosus

Gil Amarilyo, Bevra Hahn, Antonio La Cava

Research output: Contribution to journalReview articlepeer-review

Abstract

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that causes multi-organ damage and significant morbidity and mortality. Various efforts have been made to modulate the imbalanced immune responses in this disease. The manipulation of the immune system through the use of soluble synthetic peptides serving as antigenic epitopes, in repeated doses, has been shown to induce immune tolerance and to reduce the clinical manifestations of the disease in murine models. Although clinical trials in humans with the anti-DNA Ig peptide hCDR1 have failed, recent results from a clinical trial with another peptide, p140, have shown promise. This review provides an overview on the preclinical and translational work with synthetic peptides in SLE.

Original languageEnglish
Pages (from-to)1940-1947
Number of pages8
JournalFrontiers in Bioscience - Landmark
Volume17
Issue number5
DOIs
StatePublished - 1 Jan 2012
Externally publishedYes

Keywords

  • Anti-nucleosome peptide
  • Anti-RNP peptide P140
  • Anti-Sm peptide
  • HCDR1
  • PCons
  • Review
  • Synthetic peptides
  • Systemic lupus erythematosus

Fingerprint

Dive into the research topics of 'Preclinical studies with synthetic peptides in systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this